Cyclooxygenase and inflammation in Alzheimer's disease: Experimental approaches and clinical interventions

Many epidemiological studies suggest that use of non‐steroidal anti‐inflammatory drugs (NSAIDs) delay or slow the clinical expression of Alzheimer's disease (AD). While it has been demonstrated that neurodegeneration in AD is accompanied by specific inflammatory mechanisms, including activation of the complement cascade and the accumulation and activation of microglia, the mechanism by which NSAIDs might affect these or other pathophysiological processes relevant to AD has been unclear. New evidence that cyclooxygenase (COX) is involved in neurodegeneration along with the development of selective COX inhibitors has led to renewed interest in the therapeutic potential of NSAIDs in AD. J. Neurosci. Res. 54:1–6, 1998. © 1998 Wiley‐Liss, Inc.